Dr. Sarah Al-Fayed

Lead Medical Oncologist & Director of Precision Therapeutics

DepartmentComprehensive Cancer Center

Experience12+ Years

LanguagesEnglish, Arabic, French

Clinical Biography

Dr. Sarah Al-Fayed is an accomplished medical oncologist specializing in precision oncology, next-generation genomic sequencing, and targeted immunotherapies. She chairs multidisciplinary tumor boards at Aurelia Health, crafting personalized cancer treatment regimens designed to optimize tumor control while safeguarding quality of life.

Clinical Expertise & Focus

01Precision Genomic Tumor Profiling & Targeted Therapies
02Next-Generation Immune Checkpoint Inhibitor Regimens
03Breast, Gastrointestinal & Thoracic Oncology
04Integrative Supportive Cancer Care & Wellness
05Rapid Second Opinion Consultations

Education & Board Certifications

Medical Education & Fellowships

Fellowship in Medical Oncology, Memorial Sloan Kettering Cancer Center
Residency in Internal Medicine, Johns Hopkins Hospital
MD, Imperial College London School of Medicine

Board Certifications & Fellowships

Swiss Board Certified (FMH) Medical Oncology
European Society for Medical Oncology (ESMO) Certified
Member of the American Society of Clinical Oncology (ASCO)

Areas of Special Interest

Liquid Biopsy Early Recurrence Monitoring

Personalized Neoantigen Vaccine Platforms

Cardio-Oncology Heart Protection Protocols

Genetic Risk Assessment & Family Screening

Selected Research & Publications

“Genomic Biomarkers and Immune Efficacy in Solid Tumors (Journal of Clinical Oncology, 2024)”
“Targeted Kinase Inhibitors in Advanced Malignancies (Annals of Oncology, 2022)”
“Quality of Life Metrics in Contemporary Chemotherapy (The Oncologist, 2020)”